COMBINATION OF HMG-COA REDUCTASE INHIBITORS WITH PHOSPHODIESTERASE 4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PULMONARY DISEASES

• 收藏
• 分享

专利权人:

NYCOMED GMBH

发明人:

WOLLIN, STEFAN-LUTZ,WOHLSEN, ANDREA,BRAUN, CLEMENS,MARX, DEGENHARD

申请号：

NZ57337807

公开号：

NZ573378A

申请日:

2007.07.03

申请国别(地区):

NZ

年份:

2012

代理人:

摘要：

A pharmaceutical composition that comprises a PDE4 inhibitor and an HMG-CoA reductase inhibitor. The PDE4 inhibitor is 2-{ 4-[(4aS, 8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl} -acetamide and the HMG-CoA reductase inhibitor is atorvastatin. The composition is used for treating an inflammatory pulmonary disease, which can be asthma, COPD, sclerosis, alveolitits, sarcoidosis, idiopathic pulmonary fibrosis and pulmonary hypertension.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/